$IVVD
Invivyd, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023062043 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.09M $12.89M
YoY Change 43.41% -2.38%
% of Gross Profit
Research & Development $62.27M $25.57M
YoY Change 206.42% -15.12%
% of Gross Profit
Depreciation & Amortization $120.0K $120.0K
YoY Change 300.0%
% of Gross Profit
Operating Expenses $77.35M $43.06M
YoY Change 150.82% -9.02%
Operating Profit -$43.06M
YoY Change -9.02%
Interest Expense $2.700M $1.900M
YoY Change -28.95%
% of Operating Profit
Other Income/Expense, Net $398.0K $3.620M
YoY Change -102.27% 61.32%
Pretax Income -$73.65M -$39.44M
YoY Change 65.25% -12.53%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$73.65M -$39.44M
YoY Change 65.25% -12.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.36
Diluted Earnings Per Share -$0.67 -$0.36
COMMON SHARES
Basic Shares Outstanding 110.1M 109.8M
Diluted Shares Outstanding 109.8M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $200.6M $264.9M
YoY Change -46.06% -36.73%
Cash & Equivalents $200.6M $181.8M
Short-Term Investments $0.00 $83.06M
Other Short-Term Assets $23.31M $4.500M
YoY Change 417.93% 114.29%
Inventory $0.00
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $224.9M $270.1M
YoY Change -40.34% -35.93%
LONG-TERM ASSETS
Property, Plant & Equipment $4.125M $2.002M
YoY Change 80.76% 40.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $175.0K $187.0K
YoY Change -8.38% -20.76%
Total Long-Term Assets $4.300M $4.814M
YoY Change -31.2% 52.78%
TOTAL ASSETS
Total Short-Term Assets $224.9M $270.1M
Total Long-Term Assets $4.300M $4.814M
Total Assets $229.2M $274.9M
YoY Change -40.19% -35.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.953M $9.168M
YoY Change 424.26% -45.33%
Accrued Expenses $42.30M $15.96M
YoY Change 93.07% -44.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $50.29M $26.79M
YoY Change 100.91% -41.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.422M $700.0K
YoY Change
Total Long-Term Liabilities $1.422M $700.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $50.29M $26.79M
Total Long-Term Liabilities $1.422M $700.0K
Total Liabilities $51.71M $28.42M
YoY Change 90.14% -39.92%
SHAREHOLDERS EQUITY
Retained Earnings -$732.1M -$658.4M
YoY Change 37.25% 34.67%
Common Stock $909.6M $904.9M
YoY Change 2.23% 4.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $177.5M $246.5M
YoY Change
Total Liabilities & Shareholders Equity $229.2M $274.9M
YoY Change -40.19% -35.28%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$73.65M -$39.44M
YoY Change 65.25% -12.52%
Depreciation, Depletion And Amortization $120.0K $120.0K
YoY Change 300.0%
Cash From Operating Activities -$59.24M -$35.35M
YoY Change 24.96% -37.03%
INVESTING ACTIVITIES
Capital Expenditures -$5.000K $0.00
YoY Change -100.41% -100.0%
Acquisitions
YoY Change
Other Investing Activities $77.92M $95.13M
YoY Change -156.63% -167.78%
Cash From Investing Activities $77.91M $95.14M
YoY Change -156.13% -167.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 145.0K 90.00K
YoY Change 3.57% -64.0%
NET CHANGE
Cash From Operating Activities -59.24M -35.35M
Cash From Investing Activities 77.91M 95.14M
Cash From Financing Activities 145.0K 90.00K
Net Change In Cash 18.82M 59.88M
YoY Change -110.11% -130.44%
FREE CASH FLOW
Cash From Operating Activities -$59.24M -$35.35M
Capital Expenditures -$5.000K $0.00
Free Cash Flow -$59.24M -$35.35M
YoY Change 21.82% -37.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001832038
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40703
dei Entity Registrant Name
EntityRegistrantName
INVIVYD, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1403134
dei Entity Address Address Line1
EntityAddressAddressLine1
1601 Trapelo Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 178
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
819-0080
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
IVVD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
110114960
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181822000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92076000
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
83063000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
279915000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5218000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4926000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
270103000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
376917000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2002000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2282000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2625000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3777000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
187000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
191000
CY2023Q3 us-gaap Assets
Assets
274917000
CY2022Q4 us-gaap Assets
Assets
383167000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9168000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1517000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15958000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21911000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1638000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1559000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
27000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
26791000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25031000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
927000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2165000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
700000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q3 ivvd Early Exercise Liability
EarlyExerciseLiability
0
CY2022Q4 ivvd Early Exercise Liability
EarlyExerciseLiability
1000
CY2023Q3 us-gaap Liabilities
Liabilities
28418000
CY2022Q4 us-gaap Liabilities
Liabilities
27197000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109846329
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109846329
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109044046
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109044046
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
904905000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
889657000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-272000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-658415000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-533426000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
246499000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
355970000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
274917000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
383167000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109333684
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109333684
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108154397
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108154397
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.82
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109754812
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109754812
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108420674
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25574000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30131000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96393000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159295000
CY2023Q3 ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
4600000
CY2022Q3 ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
4000000
ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
5575000
ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
4000000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12886000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13200000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34038000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36524000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
43060000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
47331000
us-gaap Operating Expenses
OperatingExpenses
136006000
us-gaap Operating Expenses
OperatingExpenses
199819000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43060000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-47331000
us-gaap Operating Income Loss
OperatingIncomeLoss
-136006000
us-gaap Operating Income Loss
OperatingIncomeLoss
-199819000
CY2023Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
3620000
CY2022Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
2244000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
11017000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
3076000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3620000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2244000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11017000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3076000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-39440000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45087000
us-gaap Net Income Loss
NetIncomeLoss
-124989000
us-gaap Net Income Loss
NetIncomeLoss
-196743000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
20000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
46000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
270000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
54000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39420000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45041000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124719000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-196689000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.82
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108420674
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
558019000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
47000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1983000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-100666000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
459392000
CY2022Q2 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
76000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6361000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50990000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
414839000
CY2022Q3 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
97000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
149000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7399000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
46000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45087000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
377443000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
355970000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q1 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
459000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5400000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
83000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
157000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35321000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
326749000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q2 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
215000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4677000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
56000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
93000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-50228000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
281563000
CY2023Q3 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
35000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4264000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
57000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
20000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-39440000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
246499000
us-gaap Profit Loss
ProfitLoss
-124989000
us-gaap Profit Loss
ProfitLoss
-196743000
us-gaap Share Based Compensation
ShareBasedCompensation
14341000
us-gaap Share Based Compensation
ShareBasedCompensation
15743000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6256000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-92000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1152000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
242000
us-gaap Depreciation
Depreciation
360000
us-gaap Depreciation
Depreciation
14000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
292000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-22366000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3061000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7685000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10371000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5452000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-27554000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1159000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
222000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-18000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-53000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
700000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-113924000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-172583000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
91202000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
140360000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
294583000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
615000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
494000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
202766000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-91854000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
709000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
220000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
196000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
149000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
904000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
365000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
89746000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-264072000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92076000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
542224000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181822000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278152000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1728000
ivvd Fixed Asset Purchases In Account Payable And Accrued Expenses
FixedAssetPurchasesInAccountPayableAndAccruedExpenses
0
ivvd Fixed Asset Purchases In Account Payable And Accrued Expenses
FixedAssetPurchasesInAccountPayableAndAccruedExpenses
867000
us-gaap Net Income Loss
NetIncomeLoss
-125000000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-658400000
CY2022Q4 ivvd Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
13955000
CY2023Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1606000
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1153000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3862000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5985000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is monitoring the potential impact of the COVID-19 pandemic on its business and condensed consolidated financial statements. The Company is not aware of any specific event or circumstance that would require any update to its estimates or judgments reflected in these condensed consolidated financial statements or a revision of the carrying value of its assets or liabilities as of the issuance date of these condensed consolidated financial statements. These estimates may change as new events occur and additional information is obtained.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
ivvd Annual Gross Revenue
AnnualGrossRevenue
1235000000
CY2023Q3 us-gaap Convertible Debt
ConvertibleDebt
1000000000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
83065000
ivvd Unrealized Gain On Marketable Securities
UnrealizedGainOnMarketableSecurities
8000
ivvd Unrealized Loss On Marketable Securities
UnrealizedLossOnMarketableSecurities
10000
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
83063000
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
280187000
CY2022 ivvd Unrealized Gain On Marketable Securities
UnrealizedGainOnMarketableSecurities
52000
CY2022 ivvd Unrealized Loss On Marketable Securities
UnrealizedLossOnMarketableSecurities
324000
CY2022 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
279915000
CY2023Q3 ivvd Available For Sale Marketable Securities
AvailableForSaleMarketableSecurities
0
CY2022Q4 ivvd Available For Sale Marketable Securities
AvailableForSaleMarketableSecurities
0
CY2023Q3 ivvd Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2022Q3 ivvd Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2023Q3 ivvd Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
3265000
CY2022Q4 ivvd Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
843000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
214000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2392000
CY2023Q3 ivvd Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
1026000
CY2022Q4 ivvd Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
1314000
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
713000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
377000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5218000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4926000
CY2023Q3 ivvd Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
10278000
CY2023Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
212000
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
818000
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
15958000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
21911000
ivvd Quarterly Fee
QuarterlyFee
1300000
ivvd Delivery Fee
DeliveryFee
200000
ivvd Completion Fee
CompletionFee
200000
ivvd Exercise Fee
ExerciseFee
1000000
ivvd Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
200000
CY2022Q3 ivvd Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
3000000
CY2020Q4 ivvd Accrued Upfront Fee
AccruedUpfrontFee
200000
CY2023Q1 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
400000
CY2023Q2 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
200000
ivvd Royalty Based On Net Sales Of Licensed Products Percentage
RoyaltyBasedOnNetSalesOfLicensedProductsPercentage
0.01
us-gaap Royalty Expense
RoyaltyExpense
0
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.48
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6824712
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q3 ivvd Lessee Operating Lease Total Lease Space
LesseeOperatingLeaseTotalLeaseSpace
9600
CY2021Q3 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
400000
us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
700000
CY2022Q3 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
1300000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
430000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
275000
us-gaap Operating Lease Cost
OperatingLeaseCost
1290000
us-gaap Operating Lease Cost
OperatingLeaseCost
541000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
11000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
8000
us-gaap Variable Lease Cost
VariableLeaseCost
34000
us-gaap Variable Lease Cost
VariableLeaseCost
24000
CY2023Q3 us-gaap Lease Cost
LeaseCost
441000
CY2022Q3 us-gaap Lease Cost
LeaseCost
283000
us-gaap Lease Cost
LeaseCost
1324000
us-gaap Lease Cost
LeaseCost
565000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
432000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
275000
us-gaap Operating Lease Payments
OperatingLeasePayments
1296000
us-gaap Operating Lease Payments
OperatingLeasePayments
551000
CY2023Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
435000
CY2023Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
1521000
CY2023Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
430000
CY2023Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
328000
CY2023Q3 us-gaap Purchase Obligation
PurchaseObligation
2714000
CY2023Q3 ivvd Present Value Adjustment
PresentValueAdjustment
-149000
CY2023Q3 ivvd Present Value Of Operating Lease Liability
PresentValueOfOperatingLeaseLiability
2565000
us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.06
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.06
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1600000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
900000
CY2022Q4 ivvd Cash Fees
CashFees
3000000
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
107800000
CY2022Q2 us-gaap Purchase Obligation
PurchaseObligation
159400000
CY2023Q3 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
43362371
CY2022Q3 us-gaap Partners Capital Account Public Sale Of Units Net Of Offering Costs
PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts
400000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23239391
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.01
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1594000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5969889
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
908934
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
6253998
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.81
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22046348
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1979000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
22046348
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1979000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7624553
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.64
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
654000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.15
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.5
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
360333
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
75165
ivvd Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod
253402
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
31766
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4264000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7399000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14341000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15743000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
37300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2021Q3 ivvd Percentage Of Total Number Of Shares Of Common Stock Outstanding
PercentageOfTotalNumberOfSharesOfCommonStockOutstanding
0.01
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2685546
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-39440000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45087000
us-gaap Net Income Loss
NetIncomeLoss
-124989000
us-gaap Net Income Loss
NetIncomeLoss
-196743000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109754812
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108420674
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109333684
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108154397
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.82
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28902826
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21824702

Files In Submission

Name View Source Status
ivvd-20230930_pre.xml Edgar Link unprocessable
0000950170-23-062043-index-headers.html Edgar Link pending
0000950170-23-062043-index.html Edgar Link pending
0000950170-23-062043.txt Edgar Link pending
0000950170-23-062043-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ivvd-20230930.htm Edgar Link pending
ivvd-20230930.xsd Edgar Link pending
ivvd-ex10_2.htm Edgar Link pending
ivvd-ex10_3.htm Edgar Link pending
ivvd-ex31_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ivvd-20230930_cal.xml Edgar Link unprocessable
ivvd-20230930_def.xml Edgar Link unprocessable
ivvd-20230930_lab.xml Edgar Link unprocessable
ivvd-20230930_htm.xml Edgar Link completed
ivvd-ex31_2.htm Edgar Link pending
ivvd-ex32_1.htm Edgar Link pending
ivvd-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending